Advertisement

Side Effects, Contraindications, and Drug-Drug Interactions in the Use of Antiparkinsonian Drugs

  • Etsuro Nakanishi
  • Ryosuke TakahashiEmail author
Living reference work entry

Abstract

Since anticholinergics were firstly used as an antiparkinsonian drug over half a century ago, a lot of antiparkinsonian drugs have been developed and are now on the market. Although levodopa is most effective and still the gold standard therapy for Parkinson’s disease (PD), its side effects of motor complication such as wearing off and dyskinesia limited its use and prompted the development of novel antiparkinsonian drugs. Dopamine agonists are most commonly used drugs among them, but their serious side effects such as sleep attack and impulsive-compulsive disorders are also well-recognized. In this chapter we focus on the common and specific side effects of antiparkinsonian drugs as well as their clinically important drug-drug interactions.

References

  1. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6(9):826–9.CrossRefGoogle Scholar
  2. Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology. 2004;62(1 suppl 1):S39–46.CrossRefGoogle Scholar
  3. Ceravolo R, et al. Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study. Mov Disord. 2013;28(10):1391–7.CrossRefGoogle Scholar
  4. Cruz MP. Xadago (Safinamide). A monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson’s disease. PT. 2017;42(10):622–624,637.Google Scholar
  5. Doherty KW, et al. Postural deformities in Parkinson’s disease. Lancet Neurol. 2011;10(6):538–49.CrossRefGoogle Scholar
  6. Frucht S, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908–11.CrossRefGoogle Scholar
  7. Gibbs MB, et al. Livedo reticularis: an update. J Am Acad Dermatol. 2005;52(6):1009–19.CrossRefGoogle Scholar
  8. Giovannoni G, et al. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423–8.CrossRefGoogle Scholar
  9. Goralski KB, et al. In vivo analysis of amantadine renal clearance in the uninephrectomized rat: functional significance of in vitro bicarbonate-dependent amantadine renal tubule transport. J Pharmacol Exp Ther. 1999;290(2):496–504.Google Scholar
  10. Horn S, Stern MB. The comparative effects of medical therapies for Parkinson’s disease. Neurology. 2004;63(7 suppl 2):S7–12.CrossRefGoogle Scholar
  11. Hu XW, et al. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson’s disease: a meta-analysis. Acta Neurol Scand. 2013;128(2):73–82.CrossRefGoogle Scholar
  12. Hubsher G, et al. Amantadine. The journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096–9.CrossRefGoogle Scholar
  13. Ives NJ, et al. Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. 2004;329(7466):593.CrossRefGoogle Scholar
  14. Katzenschlager R, et al. Anticholinergics for symptomatic management of Parkinson’s disease (Cochrane Review). Cochrane Database Syst Rev. 2003;(2):CD003735.Google Scholar
  15. Knebel W, et al. Population pharmacokinetic analysis of Istradefylline in healthy subjects and in patients with Parkinson’s disease. J Clin Pharmacol. 2011;51(1):40–52.CrossRefGoogle Scholar
  16. Kondo T, et al. A long-term study of Istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol. 2015;38(2):41–6.CrossRefGoogle Scholar
  17. Molina JA, et al. Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000;15(5):869–72.CrossRefGoogle Scholar
  18. Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors. Neurology. 2003;61(11 suppl 6):S44–8.CrossRefGoogle Scholar
  19. Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson’s disease. Curr Pharm Des. 2004;10(6):687–93.CrossRefGoogle Scholar
  20. Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel Arch Neurol. 2000;57:263–7.CrossRefGoogle Scholar
  21. Pfeiffer RF, et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(2):93–100.CrossRefGoogle Scholar
  22. Pringsheim T, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.CrossRefGoogle Scholar
  23. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63.CrossRefGoogle Scholar
  24. Stowe R, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev. 2008;16(2):CD006564.Google Scholar
  25. Uncini A, et al. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry. 2015;86(5):490–5.CrossRefGoogle Scholar
  26. Warren N, et al. Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry. 2017;88(12):1060-1064.CrossRefGoogle Scholar
  27. Weintraub D, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3,090 patients. Arch Neurol. 2010;67(5):589–95.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of NeurologyKyoto University Graduate School of MedicineKyotoJapan

Section editors and affiliations

  • Toshiharu Nagatsu
    • 1
    • 2
  • Akira Nakashima
    • 3
  1. 1.Fujita Health University School of MedicineToyoakeJapan
  2. 2.Institute of Environmental MedicineNagoya UniversityNagoyaJapan
  3. 3.Department of Physiological ChemistryFujita Health University School of MedicineToyoake, AichiJapan

Personalised recommendations